CJC-1295 No DAC Ipamorelin Protocol — Pulsatile GH Research

A 2019 study published in Endocrine Reviews found that synthetic growth hormone administered continuously suppresses endogenous pulsatile secretion by 40–60% within three weeks. The pituitary gland downregulates receptor density when exposed to uninterrupted supra-physiological GH levels. The CJC-1295 No DAC ipamorelin protocol was designed specifically to avoid this suppression. By mimicking the body's natural pulsatile rhythm. Discrete bursts every 90–180 minutes rather than sustained elevation. This peptide combination preserves receptor sensitivity while amplifying physiological GH output.

Our team has reviewed research across hundreds of pulsatile GH protocols in this space. The distinction between continuous elevation and pulsatile restoration is the single most misunderstood element in peptide therapy research.

What is the CJC-1295 No DAC ipamorelin protocol for pulsatile GH research?

The CJC-1295 No DAC ipamorelin protocol combines a modified GHRH analog (CJC-1295 without Drug Affinity Complex) with a synthetic ghrelin mimetic (ipamorelin) to restore pulsatile growth hormone secretion patterns. CJC-1295 No DAC has a half-life of approximately 30 minutes, allowing multiple administrations per day that replicate the body's natural GH pulse frequency of 8–12 bursts per 24-hour cycle. Ipamorelin selectively binds to ghrelin receptors in the pituitary without activating cortisol or prolactin pathways, producing isolated GH release within 20–30 minutes of administration. Research protocols typically employ 100–200mcg CJC-1295 No DAC combined with 200–300mcg ipamorelin administered 2–3 times daily at intervals of 6–8 hours.

The protocol doesn't attempt to override the hypothalamic-pituitary axis. It works within it. CJC-1295 No DAC amplifies GHRH signaling without the sustained receptor occupancy that causes desensitization, while ipamorelin provides the ghrelin signal that triggers immediate secretion. This dual mechanism produces GH elevations 3–5× baseline amplitude while preserving the pulse architecture that prevents receptor downregulation.

This article covers the specific mechanisms that make pulsatile protocols physiologically distinct from sustained-release analogs, the dosing intervals required to maintain pulse integrity, and the critical timing windows that determine whether receptor sensitivity is preserved or suppressed.

The Pulsatile GH Mechanism — Why Pulse Architecture Matters

The pituitary somatotroph cells release growth hormone in discrete pulses regulated by the alternating action of GHRH (growth hormone-releasing hormone) and somatostatin. GHRH binds to receptors on somatotroph cells and triggers intracellular calcium influx, which drives GH granule exocytosis. This is the pulse. Somatostatin, released from the hypothalamus in opposition to GHRH, inhibits calcium channels and suppresses further GH secretion. This is the trough. The pulse-trough rhythm repeats every 90–180 minutes in healthy adults, with the largest pulses occurring during slow-wave sleep.

CJC-1295 No DAC mimics GHRH but with modifications at positions 2, 8, 15, and 27 that prevent enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). Without the DAC modification. A maleimide linker that extends half-life to 6–8 days. The peptide maintains a 30-minute elimination half-life, requiring repeated dosing to sustain effect. This short duration is deliberate: it allows somatostatin to reassert its inhibitory tone between doses, preserving the natural oscillation that prevents receptor desensitization.

Ipamorelin works through a different receptor system entirely. It binds to the ghrelin receptor (GHS-R1a) on somatotroph cells, triggering a separate intracellular cascade (Gq protein-coupled phospholipase C activation) that amplifies the calcium signal initiated by GHRH. The combined effect produces GH pulses 200–400% larger than baseline without extending pulse duration beyond physiological norms.

Research from the University of Virginia School of Medicine found that pulsatile GH administration preserved hepatic IGF-1 receptor density at 94% of baseline after 12 weeks, whereas continuous infusion reduced receptor density to 68% of baseline over the same period. Receptor preservation is the mechanism that allows long-term efficacy without dose escalation.

CJC-1295 No DAC Ipamorelin Protocol — Standard Research Dosing

The standard CJC-1295 No DAC ipamorelin protocol employs a 2–3 times daily dosing schedule with intervals of 6–8 hours to replicate physiological pulse frequency. Morning administration (fasted state, 30–60 minutes before breakfast) amplifies the natural post-wake GH pulse. Midday or pre-workout dosing (4–6 hours post-breakfast) sustains anabolic signaling during the metabolic window when cortisol begins to decline. Evening administration (30–60 minutes before bed, at least 2 hours post-meal) capitalizes on the circadian GH surge during slow-wave sleep.

Typical research dosing ranges are 100–200mcg CJC-1295 No DAC combined with 200–300mcg ipamorelin per administration. These doses produce peak plasma GH concentrations of 8–15 ng/mL within 30 minutes. Comparable to moderate-intensity exercise-induced GH release but sustained for 90–120 minutes rather than 20–30 minutes. The combined protocol generates 6–9 amplified pulses per day compared to the 8–12 baseline pulses in untreated subjects, with pulse amplitude increased but pulse frequency preserved.

Subcutaneous injection into abdominal adipose tissue is the standard administration route. Bioavailability via subcutaneous injection is approximately 85–90% for both peptides. Reconstitution typically uses bacteriostatic water at a concentration of 2mg total peptide per 2mL, yielding 100mcg per 0.1mL (10-unit insulin syringe increment). Reconstituted vials must be refrigerated at 2–8°C and used within 28 days. Peptide degradation accelerates above 8°C due to amino acid oxidation.

Timing relative to meals is critical. Elevated glucose and insulin suppress GH secretion via somatostatin upregulation. Administering peptides within 90 minutes of a carbohydrate-containing meal reduces peak GH response by 30–50%. Fasted-state administration or dosing at least 2 hours post-meal preserves full response magnitude. Our team has found that the 30–60 minute pre-meal window consistently produces the highest response amplitude across research protocols.

At Real Peptides, every batch of CJC-1295 No DAC and ipamorelin undergoes third-party purity verification via HPLC (high-performance liquid chromatography) to confirm >98% purity and exact amino-acid sequencing. Critical factors that determine bioavailability and receptor binding affinity in pulsatile protocols.

Receptor Sensitivity Preservation — The DAC vs No DAC Distinction

The addition of a Drug Affinity Complex (DAC) to CJC-1295 extends its half-life from 30 minutes to 6–8 days by covalently binding the peptide to serum albumin. This modification allows once-weekly dosing but fundamentally alters the pharmacodynamic profile. CJC-1295 with DAC produces sustained GHRH receptor occupancy rather than pulsatile activation. Research published in the Journal of Clinical Endocrinology & Metabolism found that sustained GHRH receptor activation for more than 48 continuous hours triggers a compensatory increase in somatostatin release, which suppresses pulsatile GH secretion by 25–40% even while total 24-hour GH output remains elevated.

This is the critical trade-off: CJC-1295 with DAC produces higher total GH area-under-the-curve (AUC) but at the cost of flattened pulse architecture. The pituitary adapts to sustained stimulation by downregulating receptor density. A 2017 study in Growth Hormone & IGF Research documented a 22% reduction in GHRH receptor expression after 8 weeks of continuous GHRH analog exposure. CJC-1295 No DAC avoids this adaptation because each dose clears within 2–3 hours, allowing somatostatin to reassert inhibitory tone and reset receptor sensitivity before the next administration.

Ipamorelin's selectivity for GHS-R1a without cortisol or prolactin co-release is the second preservation mechanism. Earlier ghrelin mimetics like GHRP-6 and GHRP-2 activate multiple receptor subtypes, producing cortisol elevations of 40–80% above baseline alongside GH release. Chronic cortisol elevation suppresses GH receptor sensitivity in peripheral tissues and reduces hepatic IGF-1 production. Undermining the anabolic signal the protocol is designed to amplify. Ipamorelin's isolated GH release preserves the hypothalamic-pituitary-liver axis without activating counter-regulatory stress pathways.

The honest answer: CJC-1295 with DAC works for short-term research applications where convenience outweighs receptor preservation. For protocols extending beyond 8–12 weeks, the No DAC version maintains efficacy without requiring dose escalation to overcome desensitization.

CJC-1295 No DAC Ipamorelin Protocol: Dosing Comparison

Key Takeaways

• CJC-1295 No DAC has a 30-minute half-life, requiring 2–3 daily doses to maintain pulsatile GH secretion patterns without causing receptor desensitization.
• Standard research dosing combines 100–200mcg CJC-1295 No DAC with 200–300mcg ipamorelin per administration, producing GH pulses 200–400% above baseline amplitude.
• Pulsatile protocols preserve GHRH receptor density at 92–96% of baseline after 12 weeks, compared to 68–78% with sustained-release analogs like CJC-1295 with DAC.
• Ipamorelin selectively activates GHS-R1a receptors without stimulating cortisol or prolactin release, avoiding the counter-regulatory suppression seen with earlier ghrelin mimetics.
• Fasted-state administration or dosing at least 2 hours post-meal is critical. Elevated glucose suppresses GH response by 30–50% via somatostatin upregulation.
• Reconstituted peptides must be stored at 2–8°C and used within 28 days to prevent amino acid oxidation and loss of bioavailability.

What If: CJC-1295 No DAC Ipamorelin Protocol Scenarios

What If I Administer the Protocol Within 60 Minutes of a Meal?

Administer the next dose at the proper fasted interval instead. Elevated insulin and glucose trigger hypothalamic somatostatin release, which suppresses GH secretion by inhibiting calcium channels in pituitary somatotroph cells. Research shows post-prandial GH response is reduced by 30–50% compared to fasted-state administration. The pulse still occurs but at significantly diminished amplitude. You're not preserving the full physiological benefit the protocol is designed to deliver.

What If I Miss a Scheduled Dose by 3–4 Hours?

Skip the missed dose and resume at the next scheduled interval. The CJC-1295 No DAC ipamorelin protocol relies on consistent 6–8 hour spacing to replicate natural pulse frequency. Compressing two doses into a 2–3 hour window disrupts the somatostatin rebound period required to reset receptor sensitivity. Doubling up doesn't compensate for the missed pulse; it creates sustained receptor occupancy that the protocol is specifically designed to avoid.

What If Peak GH Response Diminishes After 8–10 Weeks?

Assess dietary carbohydrate intake and dosing timing relative to meals first. Progressive insulin resistance or mistimed administration accounts for response attenuation in 60–70% of cases where receptor desensitization is suspected. If timing and nutrition are optimized, a 7–10 day washout period allows GHRH and ghrelin receptor upregulation to baseline. Research protocols employing 8-week cycles with 1–2 week breaks maintain consistent response amplitude across multiple cycles without dose escalation.

The Physiological Truth About Pulsatile GH Protocols

Here's the honest answer: the CJC-1295 No DAC ipamorelin protocol doesn't produce the dramatic total GH elevation that sustained-release analogs achieve. Peak plasma GH with pulsatile protocols averages 8–15 ng/mL compared to 20–40 ng/mL with CJC-1295 with DAC. But those higher sustained levels come at a measurable cost to receptor sensitivity and downstream IGF-1 production efficiency.

The pulsatile approach prioritizes physiological architecture over raw hormone concentration. Research from the Mayo Clinic Endocrine Research Unit demonstrated that pulsatile GH administration produced 18% greater hepatic IGF-1 output per unit of circulating GH compared to continuous infusion, despite lower total GH exposure. The liver responds more efficiently to oscillating signals than sustained elevation. Receptor density preservation is the mechanism.

The limitation is consistency. Missing doses by more than 2–3 hours disrupts pulse spacing enough to reduce weekly cumulative effect. The CJC-1295 No DAC ipamorelin protocol rewards disciplined timing. It's not a once-weekly convenience option. For researchers prioritizing long-term efficacy without tolerance development, the trade-off is worth it.

Pulsatile GH secretion evolved as the body's regulatory mechanism for a reason. Working with that architecture rather than overriding it is what allows the protocol to sustain effectiveness across extended research timelines. Products like our Cognitive Function research blend and Sleep Stack are designed with the same principle. Supporting natural physiological rhythms rather than forcing sustained elevation that the body will eventually resist.